1183.6000 15.40 (1.32%)
NSE Nov 12, 2025 15:31 PM
Volume: 2.4M
 

1183.60
1.32%
ICICI Direct
Q2FY26- Muted numbers on expected lines Revenues grew ~6% YoY to 8286 crore due to softness in the US (44% of the revenues) which grew 3% to 3638 crore. Europe (30% of the revenues) grew 18% to 2480 crore and ARV (~4% of the revenues) grew 68% to 325 crore. Growth Markets (~10% of the revenues) grew ~9% YoY to 882 crore (including India formulations). APIs de-grew at 17% YoY to 961 crores. EBITDA grew 7% YoY to 1678 crore while EBITDA margins increased 16 bps to 20.3%. EBITDA de-growth was mainly driven by increase in employee expenses....
Aurobindo Pharma Ltd. is trading above all available SMAs
More from Aurobindo Pharma Ltd.
Recommended